AU2005289728B2 - Methods and compositions for evaluating breast cancer prognosis - Google Patents

Methods and compositions for evaluating breast cancer prognosis Download PDF

Info

Publication number
AU2005289728B2
AU2005289728B2 AU2005289728A AU2005289728A AU2005289728B2 AU 2005289728 B2 AU2005289728 B2 AU 2005289728B2 AU 2005289728 A AU2005289728 A AU 2005289728A AU 2005289728 A AU2005289728 A AU 2005289728A AU 2005289728 B2 AU2005289728 B2 AU 2005289728B2
Authority
AU
Australia
Prior art keywords
biomarkers
breast cancer
biomarker
prognosis
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005289728A
Other languages
English (en)
Other versions
AU2005289728A1 (en
Inventor
Timothy J. Fischer
Douglas P. Malinowski
Raphael Marcelpoil
Didier Morel
Clark M. Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TriPath Imaging Inc
Original Assignee
TriPath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TriPath Imaging Inc filed Critical TriPath Imaging Inc
Publication of AU2005289728A1 publication Critical patent/AU2005289728A1/en
Application granted granted Critical
Publication of AU2005289728B2 publication Critical patent/AU2005289728B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AU2005289728A 2004-09-22 2005-09-22 Methods and compositions for evaluating breast cancer prognosis Ceased AU2005289728B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61207304P 2004-09-22 2004-09-22
US61196504P 2004-09-22 2004-09-22
US60/612,073 2004-09-22
US60/611,965 2004-09-22
PCT/US2005/034152 WO2006036788A2 (en) 2004-09-22 2005-09-22 Methods and compositions for evaluating breast cancer prognosis

Publications (2)

Publication Number Publication Date
AU2005289728A1 AU2005289728A1 (en) 2006-04-06
AU2005289728B2 true AU2005289728B2 (en) 2011-11-24

Family

ID=35695736

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005289728A Ceased AU2005289728B2 (en) 2004-09-22 2005-09-22 Methods and compositions for evaluating breast cancer prognosis
AU2005289756A Expired AU2005289756B2 (en) 2004-09-22 2005-09-22 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005289756A Expired AU2005289756B2 (en) 2004-09-22 2005-09-22 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis

Country Status (11)

Country Link
US (3) US7899623B2 (de)
EP (2) EP1800130B1 (de)
JP (2) JP5184087B2 (de)
KR (2) KR20070068401A (de)
AT (1) ATE520988T1 (de)
AU (2) AU2005289728B2 (de)
BR (2) BRPI0515562A (de)
CA (2) CA2580795A1 (de)
IL (2) IL182062A0 (de)
MX (1) MX2007003502A (de)
WO (2) WO2006036788A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8594410B2 (en) * 2006-08-28 2013-11-26 Definiens Ag Context driven image mining to generate image-based biomarkers
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP2027465A2 (de) 2006-05-17 2009-02-25 Cellumen, Inc. Verfahren für automatisierte gewebeanalyse
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
EP2041574B1 (de) 2006-07-14 2016-11-16 The Regents of The University of California Krebsbiomarker und anwendungsverfahren dafür
WO2008019375A2 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
WO2008043104A2 (en) * 2006-10-06 2008-04-10 Applied Genomics Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
CA2690612C (en) 2007-05-14 2016-07-05 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
ES2599902T3 (es) * 2007-06-15 2017-02-06 Novartis Ag Sistema y método de microscopio para obtener datos de muestra normalizados
US20100221722A1 (en) * 2007-06-15 2010-09-02 University Of North Carolina At Chapel Hill Methods for evaluating breast cancer prognosis
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) * 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2034027A1 (de) * 2007-09-04 2009-03-11 Siemens Healthcare Diagnostics GmbH Molekulare Marker zur Vorhersage der Reaktion auf eine Chemotherapie und Hemmung der EGFR-Familie durch gezielte Strategien
EP2185728A2 (de) * 2007-09-07 2010-05-19 Université Libre de Bruxelles Verfahren und werkzeuge zur prognose von krebs bei er-patienten
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009055480A2 (en) * 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
AU2009262022A1 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis and methods of use thereof
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP5551702B2 (ja) * 2008-09-16 2014-07-16 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量
WO2010062705A1 (en) * 2008-11-03 2010-06-03 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
US20100124747A1 (en) * 2008-11-03 2010-05-20 University Of Southern California Compositions and methods for diagnosis or prognosis of testicular cancer
KR101141103B1 (ko) * 2009-12-15 2012-05-02 계명대학교 산학협력단 임상진단 결정 규칙 생성 방법
EP2845911B1 (de) * 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Verfahren zur Vorhersage des Rückkehr von Brustkrebs unter Endocrinbehandlung
US12571798B2 (en) * 2010-04-27 2026-03-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US9129426B2 (en) 2010-08-31 2015-09-08 General Electric Company Motion compensation in image processing
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
US20130096021A1 (en) * 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
WO2013067198A1 (en) * 2011-11-01 2013-05-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of nf-kappab activity
EP2773390B1 (de) * 2011-11-03 2020-12-30 Tripath Imaging, Inc. Verfahren und zusammensetzungen zur vorbereitung von proben auf die immunoeinfärbung
US8885912B2 (en) * 2011-11-03 2014-11-11 General Electric Company Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique
US20150184247A1 (en) * 2012-04-20 2015-07-02 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
EP2845139A2 (de) * 2012-04-30 2015-03-11 General Electric Company Systeme und verfahren zur durchführung einer korrelationsanalyse klinischer ergebnisse und der eigenschaften von biologischem gewebe
US8737709B2 (en) * 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014016401A1 (en) * 2012-07-27 2014-01-30 Centre Leon Berard DETECTION OF THE ERα/SRC/PI3K COMPLEX AS PREDICTIVE MARKER IN BREAST CANCER
JP2014123230A (ja) * 2012-12-20 2014-07-03 Sony Corp 画像処理装置、画像処理方法、及び、プログラム
CN103136333B (zh) * 2013-01-29 2016-08-10 冯力新 一种抽象属性的量化评价分析方法
CN103293321B (zh) * 2013-05-27 2015-05-13 北京大学 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
US9519823B2 (en) * 2013-10-04 2016-12-13 The University Of Manchester Biomarker method
US9953417B2 (en) 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
US9785752B1 (en) * 2014-02-25 2017-10-10 Flagship Biosciences, Inc. Method for stratifying and selecting candidates for receiving a specific therapeutic approach
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US20170176440A1 (en) * 2014-03-27 2017-06-22 The Board Of Regents Of The University Of Texas System Methods and compositions for evaluating breast cancer patients
EP3155592B1 (de) 2014-06-10 2019-09-11 Leland Stanford Junior University Vorhersage von brustkrebswiederauftreten direkt von bildmerkmalen, die von digitalisierten immunohistopathologiegewebedias berechnet werden
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
WO2016123525A1 (en) * 2015-01-30 2016-08-04 Raytheon Company Apparatus and methods for classifying and counting corn kernels
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
WO2017091658A1 (en) 2015-11-25 2017-06-01 Cernostics, Inc. Methods of predicting progression of barrett's esophagus
KR20180091024A (ko) * 2015-12-02 2018-08-14 클리어라이트 다이어그노스틱스 엘엘씨 암의 검출 및 모니터링을 위해 종양 조직 시료를 준비하고 분석하는 방법
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
MX2018009566A (es) 2016-02-08 2019-05-30 Imago Systems Inc Sistema y metodo para la visualizacion y caracterizacion de objetos en imagenes.
EP3430384A4 (de) * 2016-03-14 2019-07-31 Proteocyte Diagnostics Inc. Automatisiertes verfahren zur beurteilung des krebsrisikos mithilfe von gewebeproben und system dafür
SG10201911357VA (en) 2016-03-14 2020-01-30 Somalogic Inc Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence
JP2019515265A (ja) * 2016-04-20 2019-06-06 エーザイ インク． バイオマーカーを使用する漿液性卵巣がんの予後
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
JP2020533039A (ja) 2017-08-07 2020-11-19 イマーゴ・システムズ，インコーポレーテッド 画像中の物体の視覚化および特徴づけのためのシステムおよび方法
US20220187301A1 (en) 2018-09-14 2022-06-16 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
WO2020124084A1 (en) * 2018-12-15 2020-06-18 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
US20230340608A1 (en) 2020-07-17 2023-10-26 European Molecular Biology Laboratory Prognostic biomarkers for cancer
CN114959026A (zh) * 2022-04-15 2022-08-30 深圳市陆为生物技术有限公司 检测基因的试剂在制备用于评价乳腺癌患者复发风险的产品中的应用
EP4646208A1 (de) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Behandlung von er+-brustkrebs mit mangel an homologer rekombination unter verwendung eines parg-hemmers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1994000591A1 (fr) * 1992-06-26 1994-01-06 Nippon Shinyaku Co., Ltd. Anticorps monoclonal, son procede d'obtention, cellule productrice de cet anticorps, et methode de diagnostic
DK0745243T3 (da) * 1994-02-14 2004-04-19 Autocyte North Carolina Llc Fremgangsmåder til automatiseret klassificering af cytologiske prøver
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
JP2002514098A (ja) * 1996-08-25 2002-05-14 センサー インコーポレイテッド 虹彩取得用イメージのための装置
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
JP2001504233A (ja) * 1996-11-22 2001-03-27 シルーヴ メディカル テクノロジーズ リミテッド 癌を有する被験者の早期検出のための全血／マイトジェンアッセイおよびキット
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
EP1159619A2 (de) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Verfahren zur diagnose und zum behandeln von brustkrebs
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
AU781992B2 (en) * 2000-04-04 2005-06-23 Medical Research Council Methods involving induced dimerisation by cellular components
ES2232613T3 (es) * 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
WO2002008765A2 (en) * 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
US6703204B1 (en) * 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
EP1410011B1 (de) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnose und prognose von brustkrebspatientinnen
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP3721105B2 (ja) * 2001-08-22 2005-11-30 日本電気株式会社 組織検査法を利用する胃癌の切除手術後の予後検査方法
US7065236B2 (en) 2001-09-19 2006-06-20 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7133547B2 (en) 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
AU2003217397A1 (en) * 2002-02-14 2003-09-04 The Johns Hopkins University School Of Medecine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1613205B1 (de) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb-oberflächen-rezeptor-komplexe als biomarker
WO2005049022A2 (en) * 2003-11-17 2005-06-02 Novartis Ag Use of dipeptidyl peptidase iv inhibitors
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
ES2381644T3 (es) * 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhang SY et al, CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, 2000, 9:395-401 *

Also Published As

Publication number Publication date
EP1800130A2 (de) 2007-06-27
BRPI0515581A (pt) 2008-07-29
KR20070068401A (ko) 2007-06-29
IL182063A0 (en) 2008-04-13
WO2006036788A3 (en) 2006-08-17
EP1805676A1 (de) 2007-07-11
US20060078926A1 (en) 2006-04-13
JP2008513032A (ja) 2008-05-01
ATE520988T1 (de) 2011-09-15
CA2580937C (en) 2016-02-02
JP2008513793A (ja) 2008-05-01
AU2005289728A1 (en) 2006-04-06
AU2005289756B2 (en) 2011-10-13
KR20070061893A (ko) 2007-06-14
AU2005289756A1 (en) 2006-04-06
WO2006036788A2 (en) 2006-04-06
CA2580937A1 (en) 2006-04-06
US7899623B2 (en) 2011-03-01
US20090269856A1 (en) 2009-10-29
EP1800130B1 (de) 2011-08-17
BRPI0515562A (pt) 2008-07-29
MX2007003502A (es) 2007-10-10
JP5184087B2 (ja) 2013-04-17
CA2580795A1 (en) 2006-04-06
WO2006036726A1 (en) 2006-04-06
US20060063190A1 (en) 2006-03-23
IL182062A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
AU2005289728B2 (en) Methods and compositions for evaluating breast cancer prognosis
US10494677B2 (en) Predicting cancer outcome
US20070218512A1 (en) Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
DK2726635T3 (en) Multigen prognosetest for lungecancer
US20100196902A1 (en) Prostate cancer biomarkers
US8076077B2 (en) Compositions and methods for prognosis and therapy of liver cancer
US20110224313A1 (en) Compositions and methods for classifying lung cancer and prognosing lung cancer survival
US20100105564A1 (en) Stroma Derived Predictor of Breast Cancer
Rosa Advances in the molecular analysis of breast cancer: pathway toward personalized medicine
CN101675341A (zh) 癌症的生物标志物
US20150344962A1 (en) Methods for evaluating breast cancer prognosis
WO2012009382A2 (en) Molecular indicators of bladder cancer prognosis and prediction of treatment response
Zhang et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer
JP2005523727A (ja) 腫瘍のバイオマーカーを発見して腫瘍を診断する方法
US20140127708A1 (en) Predictive biomarkers for prostate cancer
EP2278026A1 (de) Verfahren zur Vorhersage des klinischen Ergebnisses von Patienten mit Brustkarzinom
CN101057144A (zh) 用于评价乳腺癌预后的方法和组合物
WO2015006262A1 (en) Tumor tissue analysis techniques
JP7216995B2 (ja) 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
CN100549172C (zh) 用于肝癌的预后和治疗的组合物和方法
EP1470419A1 (de) Verfahren zur prognose gastrointestinalen tumoren
JP2022032795A (ja) 子宮内膜癌の発症の予測方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired